Earnings ·
PRF Technologies Ltd. reported unaudited financial results for the six months ended June 30, 2026, recording a net…
PRFXPRF Technologies Ltd.
PRF Technologies Ltd. reported unaudited financial results for the six months ended June 30, 2026, recording a net loss of $2.8 million compared to $2.3 million in the prior year period. The company raised approximately $10.4 million through equity financing activities, including the full utilization of a May Standby Equity Purchase Agreement (SEPA) with Yorkville for $10.0 million and initial draws under a June SEPA totaling $447,000. Cash and equivalents increased to $8.5 million as of June 30, 2026. Operationally, the company received FDA clearance for its IND application for OcuRing™-K, enabling Phase II trial enrollment in late 2026, while PRF-110 demonstrated analgesic activity comparable to ZYNRELEF® in preclinical studies. DeepSolar generated early revenue from commercial engagements and unveiled new AI platforms. The company operates in the specialty pharmaceuticals and AI-driven energy analytics sectors.